Alectinib, ceritinib, elotuzumab, and venetoclax

James Waddell, Dominic A. Solimando

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

Original languageEnglish (US)
Pages (from-to)524-534
Number of pages11
JournalHospital Pharmacy
Volume51
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Poisons
Pharmacists
Antineoplastic Agents
Drug Therapy
Chemotherapy
Neoplasms
Therapeutics
ceritinib
elotuzumab
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
CH5424802

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Alectinib, ceritinib, elotuzumab, and venetoclax. / Waddell, James; Solimando, Dominic A.

In: Hospital Pharmacy, Vol. 51, No. 7, 01.07.2016, p. 524-534.

Research output: Contribution to journalReview article

Waddell, James ; Solimando, Dominic A. / Alectinib, ceritinib, elotuzumab, and venetoclax. In: Hospital Pharmacy. 2016 ; Vol. 51, No. 7. pp. 524-534.
@article{040a7f02c20744768beeac594c1b2bdc,
title = "Alectinib, ceritinib, elotuzumab, and venetoclax",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.",
author = "James Waddell and Solimando, {Dominic A.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1310/hpj5107-524",
language = "English (US)",
volume = "51",
pages = "524--534",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "7",

}

TY - JOUR

T1 - Alectinib, ceritinib, elotuzumab, and venetoclax

AU - Waddell, James

AU - Solimando, Dominic A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

UR - http://www.scopus.com/inward/record.url?scp=84986550326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986550326&partnerID=8YFLogxK

U2 - 10.1310/hpj5107-524

DO - 10.1310/hpj5107-524

M3 - Review article

VL - 51

SP - 524

EP - 534

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 7

ER -